Anti-VEGF therapies are emerging as one of the latest trends in targeting lung cancer (Frezzetti et al., 2017; Yang et al., 2017; Jeong et al., 2020; Seitlinger et al., 2022). This evidence concerns the gene VEGFA and lung carcinoma.